LoginSignup
Blueprint logo

Blueprint Stock

StockStock
ISIN: US09627Y1091
Ticker: BPMC
US09627Y1091
BPMC

Price

Frequently asked questions

What is Blueprint's market capitalization?

The market capitalization of Blueprint is $6.15B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Blueprint?

Blueprint's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.108. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Blueprint's stock?

Currently, 18 analysts cover Blueprint's stock, with a consensus target price of $119.41. Analyst ratings provide insights into the stock's expected performance.

What is Blueprint's revenue over the trailing twelve months?

Over the trailing twelve months, Blueprint reported a revenue of $434.41M.

What is the EBITDA for Blueprint?

Blueprint's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$262.13M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Blueprint?

Blueprint has a free cash flow of -$250.52M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Blueprint's stock?

The 5-year beta for Blueprint is 0.58. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Blueprint have, and what sector and industry does it belong to?

Blueprint employs approximately 638 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Blueprint's shares?

The free float of Blueprint is 62.95M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $6.15B

5Y beta

 0.58

EPS (TTM)

 -$2.108

Free Float

 62.95M

Revenue (TTM)

 $434.41M

EBITDA (TTM)

 -$262.13M

Free Cashflow (TTM)

 -$250.52M

Pricing

52W span
$63.07$121.90

Analyst Ratings

The price target is $119.41 and the stock is covered by 18 analysts.

Buy

13

Hold

4

Sell

1

Information

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

638

Biotechnology & Drugs

Health Care

Identifier

ISIN

US09627Y1091

Primary Ticker

BPMC

Knockouts

Join the conversation
Sign upLogin